Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Nuvation Bio Inc. (NUVB:NYSE), powered by AI.
Nuvation Bio Inc. is currently trading at $5.12. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Nuvation Bio Inc. on Alpha Lenz.
View Nuvation Bio Inc.'s valuation metrics on Alpha Lenz.
“Nuvation Bio Inc.'s ROE is -53.2%. Explore profitability and growth together.”
Ask for details →Nuvation Bio Inc. is a biopharmaceutical company focused on developing innovative therapies for oncology patients. Its primary purpose is to research and advance novel drug candidates targeting various forms of cancer, particularly those for which few treatments currently exist. The company's pipeline is centered on next-generation therapies, including small molecules and targeted drugs designed to enhance and extend the lives of cancer patients. Operating in the highly competitive and scientifically rigorous field of biotechnology, Nuvation Bio Inc. collaborates with leading experts in oncological research to bring promising treatments to clinical trials. Its strategic focus on areas like neuroendocrine tumors and advanced prostate cancer highlights its dedication to addressing unmet medical needs. In the financial markets, Nuvation Bio Inc. holds significance due to its potential impact on the healthcare sector, particularly through the development of breakthrough cancer therapies that could transform treatment paradigms. The company's progress is closely followed by investors and stakeholders interested in the future of cancer treatment innovation.
“Nuvation Bio Inc.'s ROE is -53.2%. Explore profitability and growth together.”
Ask for details →Nuvation Bio Inc. (ticker: NUVB) is a company listed on NYSE in the Healthcare sector (Biotechnology). It has approximately 278 employees.
The current price is $5.12 with a P/E ratio of -x and P/B of -x.
ROE is -53.18% and operating margin is -338.72%. Annual revenue is $63M.